Cargando…

RNAi Therapeutics in Autoimmune Disease

Since the discovery of RNA interference (RNAi), excitement has grown over its potential therapeutic uses. Targeting RNAi pathways provides a powerful tool to change biological processes post-transcriptionally in various health conditions such as cancer or autoimmune diseases. Optimum design of shRNA...

Descripción completa

Detalles Bibliográficos
Autores principales: Pauley, Kaleb M., Cha, Seunghee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3816694/
https://www.ncbi.nlm.nih.gov/pubmed/24276020
http://dx.doi.org/10.3390/ph6030287
_version_ 1782477974386245632
author Pauley, Kaleb M.
Cha, Seunghee
author_facet Pauley, Kaleb M.
Cha, Seunghee
author_sort Pauley, Kaleb M.
collection PubMed
description Since the discovery of RNA interference (RNAi), excitement has grown over its potential therapeutic uses. Targeting RNAi pathways provides a powerful tool to change biological processes post-transcriptionally in various health conditions such as cancer or autoimmune diseases. Optimum design of shRNA, siRNA, and miRNA enhances stability and specificity of RNAi-based approaches whereas it has to reduce or prevent undesirable immune responses or off-target effects. Recent advances in understanding pathogenesis of autoimmune diseases have allowed application of these tools in vitro as well as in vivo with some degree of success. Further research on the design and delivery of effectors of RNAi pathway and underlying molecular basis of RNAi would warrant practical use of RNAi-based therapeutics in human applications. This review will focus on the approaches used for current therapeutics and their applications in autoimmune diseases, including rheumatoid arthritis and Sjögren’s syndrome.
format Online
Article
Text
id pubmed-3816694
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-38166942013-11-14 RNAi Therapeutics in Autoimmune Disease Pauley, Kaleb M. Cha, Seunghee Pharmaceuticals (Basel) Review Since the discovery of RNA interference (RNAi), excitement has grown over its potential therapeutic uses. Targeting RNAi pathways provides a powerful tool to change biological processes post-transcriptionally in various health conditions such as cancer or autoimmune diseases. Optimum design of shRNA, siRNA, and miRNA enhances stability and specificity of RNAi-based approaches whereas it has to reduce or prevent undesirable immune responses or off-target effects. Recent advances in understanding pathogenesis of autoimmune diseases have allowed application of these tools in vitro as well as in vivo with some degree of success. Further research on the design and delivery of effectors of RNAi pathway and underlying molecular basis of RNAi would warrant practical use of RNAi-based therapeutics in human applications. This review will focus on the approaches used for current therapeutics and their applications in autoimmune diseases, including rheumatoid arthritis and Sjögren’s syndrome. MDPI 2013-03-05 /pmc/articles/PMC3816694/ /pubmed/24276020 http://dx.doi.org/10.3390/ph6030287 Text en © 2013 by the authors; licensee MDPI, Basel, Switzerland. http://creativecommons.org/licenses/by/3.0/ This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Review
Pauley, Kaleb M.
Cha, Seunghee
RNAi Therapeutics in Autoimmune Disease
title RNAi Therapeutics in Autoimmune Disease
title_full RNAi Therapeutics in Autoimmune Disease
title_fullStr RNAi Therapeutics in Autoimmune Disease
title_full_unstemmed RNAi Therapeutics in Autoimmune Disease
title_short RNAi Therapeutics in Autoimmune Disease
title_sort rnai therapeutics in autoimmune disease
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3816694/
https://www.ncbi.nlm.nih.gov/pubmed/24276020
http://dx.doi.org/10.3390/ph6030287
work_keys_str_mv AT pauleykalebm rnaitherapeuticsinautoimmunedisease
AT chaseunghee rnaitherapeuticsinautoimmunedisease